Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2023202220212020 February 2, 2023 Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day January 30, 2023 Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer December 1, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology November 3, 2022 Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview September 6, 2022 Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview June 21, 2022 Protara Therapeutics Announces Departure of Chief Financial Officer May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting May 17, 2022 Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 13 - 24 of 70 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2023202220212020 February 2, 2023 Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day January 30, 2023 Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer December 1, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology November 3, 2022 Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview September 6, 2022 Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview June 21, 2022 Protara Therapeutics Announces Departure of Chief Financial Officer May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting May 17, 2022 Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 13 - 24 of 70
January 30, 2023 Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
December 1, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
November 3, 2022 Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
September 6, 2022 Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
